BioLume®, Inc. is a private biotechnology company located in Research Triangle Park, NC. Our mission is to develop and commercialize a portfolio of proprietary bioluminescent (light producing/glowing) proteins and related substrates with many first-in-class applications in the food, beverage, and cosmetic, plus diagnostic imaging, markets.
What is Bioluminescence?
Bioluminescence is "cold" light produced by a chemical reaction within a living organism. Unlike fluorescence, bioluminescence does not require energy from another source of light to create illumination. As a result, bioluminescence has a much greater range of uses than fluorescence. BioLume’s bioluminescent proteins were cloned from deep-sea marine organisms and are all natural chemistry that is prominent in the ocean’s food chain, and thus routinely consumed by man in many species of fish. Bioluminescence is not radioactive.
BioLume has been assigned or exclusively licensed, worldwide, a large portfolio of more than forty (40) U.S. and foreign patents by Prolume, Ltd. These include both compositions of matter and methods of use patents specific to the applications above. Prolume is a private biotechnology company that discovered, developed, and commercialized these same bioluminescent proteins for biomedical research and drug discovery. Major pharmaceutical companies have routinely used these proteins for years in a number of life science applications related to drug discovery.
Biolume's Market Opportunities
The consumer markets covered within BioLume’s exclusive field of use are very large and growing. The broad and diverse consumer applications within foods, beverages, and cosmetics represent huge first-in-class product opportunities. There are no consumable bioluminescent products on the market today. BioLume has trademarked the brand name Lumoness™ for the combination of chemistry that produces the bright, luminescent glow, in a spectrum of colors, which can be added to a broad range of food, beverage, and cosmetic products. Many major consumer companies preliminarily have expressed interest in Lumoness because “there aren’t any new foods, just new ingredients.”
Biolume bioluminescent proteins have broad application in diagnostic imaging including anatomic, vascular and molecular imaging. Molecular imaging represents a paradigm shift in the focus of medical imaging from the visualization of anatomy and physiology to the study of metabolic and physiological processes, such as cancers, at the cellular level, often in real time. Molecular imaging, and specifically bioluminescent imaging (BLI), allows for early diagnosis of disease before there are symptoms or anatomic masses such as tumors. Plus, BLI can be used to quantitatively monitor disease progression and the efficacy of drug therapy non-invasively. Optical imaging systems are already marketed that can detect light transmitted through tissue. Many peer-reviewed publications on the subject, most using BioLume’s proprietary technology, witness BLI interest. The brand name TumorLight™ has been trademarked for diagnostic imaging applications.